Halozyme Therapeutics (HALO) free cash flow
Halozyme Therapeutics (HALO) generated free cash flow of $356.82M in fiscal 2025 (the year ended December 31, 2025). That is 23.8% lower than the $468.37M of fiscal 2024. Figures as of 18 Nov 2026, 12:20 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Free cash flow, fiscal 2025
- $356.82M
- Change on fiscal 2024
- −23.8%
- Growth, 5 years
- +46.5% a year
- Highest on record
- $468.37Mfiscal 2024
- Lowest on record
- -$89.46Mfiscal 2019
- Fiscal years on record
- 172009–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Halozyme Therapeutics free cash flow, in more detail
Over the five fiscal years to 2025 free cash flow grew at a compound 46.5% a year. Across the 17 fiscal years on record (2009–2025), the highest was $468.37M in fiscal 2024 and the lowest -$89.46M in fiscal 2019.
Free cash flow by fiscal year
Halozyme Therapeutics free cash flow, year by year
| Fiscal year | Free cash flow | Change | Year ended |
|---|---|---|---|
| 2025 | $356.82M | 23.8% down | |
| 2024 | $468.37M | 25.5% up | |
| 2023 | $373.28M | 58.6% up | |
| 2022 | $235.30M | 21.0% down | |
| 2021 | $297.98M | 462.8% up | |
| 2020 | $52.95M | — | |
| 2019 | -$89.46M | — | |
| 2018 | -$54.16M | 140.8% down | |
| 2017 | $132.70M | — | |
| 2016 | -$53.52M | — | |
| 2015 | -$39.44M | — | |
| 2014 | -$48.89M | — | |
| 2013 | -$51.64M | — | |
| 2012 | -$65.69M | — | |
| 2011 | -$35.13M | — | |
| 2010 | -$46.03M | — | |
| 2009 | -$41.61M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.
How to read it
It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.
Free cash flow at health care companies of similar size
| Company | Free cash flow | Fiscal year |
|---|---|---|
| Fresenius Medical Care FMS | €1.77B | 2025 |
| Kymera Therapeutics KYMR | -$234.34M | 2025 |
| DaVita DVA | $1.31B | 2025 |
| Halozyme Therapeutics HALO | $356.82M | 2025 |
| Universal Health Services UHS | $824.55M | 2025 |
| Repligen RGEN | $91.69M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Halozyme Therapeutics, figure by figure
- Halozyme Therapeutics market cap
- Halozyme Therapeutics revenue
- Halozyme Therapeutics earnings
- Halozyme Therapeutics earnings per share (EPS)
- Halozyme Therapeutics P/E ratio
- Halozyme Therapeutics P/S ratio
- Halozyme Therapeutics P/B ratio
- Halozyme Therapeutics operating margin
- Halozyme Therapeutics dividend
- Halozyme Therapeutics shares outstanding
- Halozyme Therapeutics total debt
- Halozyme Therapeutics cash on hand
- Halozyme Therapeutics total assets
- Halozyme Therapeutics return on equity (ROE)
- Halozyme Therapeutics return on invested capital (ROIC)
Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value
Halozyme Therapeutics free cash flow: questions and answers
What is Halozyme Therapeutics's free cash flow?
Halozyme Therapeutics (HALO) generated free cash flow of $356.82M in fiscal 2025 (the year ended December 31, 2025). That is 23.8% lower than the $468.37M of fiscal 2024.
What is the growth rate of Halozyme Therapeutics's free cash flow?
Over the five fiscal years to 2025 free cash flow grew at a compound 46.5% a year.
What are the highest and lowest free cash flow figures on record for Halozyme Therapeutics?
Across the 17 fiscal years on record (2009–2025), the highest was $468.37M in fiscal 2024 and the lowest -$89.46M in fiscal 2019.
How is Halozyme Therapeutics's free cash flow calculated?
Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Halozyme Therapeutics it is on record here for 17 fiscal years, 2009 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: free cash flow
All stocks guides →- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
- How a DCF valuation works, and why inputs swing it
A discounted cash flow (DCF) valuation estimates what a business is worth today by forecasting the cash it will produce and discounting each year's cash back at a required rate of return. Because most of the value lies far in the future, a one-point change in growth or discount rate can move the answer by a quarter.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Halozyme Therapeutics (HALO) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/free-cash-flow
Underlying data: the company's filings with the SEC and Yahoo Finance.